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Despite the ever-increasing interest in membrane protein struc-
tures and functions, interactions mediated by transmembrane
domains (TMDs) remain poorly understood. Homo- and hetero-
oligomerizations via TMDs play key roles in the function of many
integral membrane proteins of therapeutic interest, such as G protein-
coupled receptors (GPCRs) [1] and transporters [2]. The groups of
Langosch and Engelman developed the ToxR/ToxCAT assays which
enable measurement of the strength of transmembrane helix in-
teractions in the natural phospholipid environment of the E. coli inner
membrane [3,4]. TMD-induced oligomerization of a chimeric protein
comprised of maltose binding protein (MBP) for localization to the
periplasm fused to the TMD of interest and cytosolic ToxR, results in
proximity-induced dimerization of ToxR. Dimeric ToxR binds to the
ctx promoter and downstream signaling can be measured by a variety
of methods (Fig. 1a). More recently, the teams led by Engelman and
Dixon demonstrated that signaling via ToxR can be driven by not only
simple dimerization but also higher order association (e.g. trimeriza-
tion) [5,6] of the TMD. In the past decade, further work by the groups
of Engelman and Langosch as well as others (such as Shai, Dixon,
Flemming, MacKenzie, Schneider, and DeGrado) have signiﬁcantlyimproved the ToxR family of assays that have become a crucial tool in
the elucidation of function of a wide range of integral membrane
proteins [7–11]. However, previously only single-pass transmem-
brane systems have been investigated using ToxR/ToxCAT assays.
Since 53% of human membrane proteins are predicted to have more
than one transmembrane helix [12], an assay designed to studymulti-
pass TMD interactions will provide valuable functional information on
proteins that are inherently difﬁcult to study by conventional
techniques. To facilitate investigation of membrane protein–protein
interactions, we applied the ToxR transcriptional reporter assay to the
study of polytopic TMD oligomerization in biological membranes and
named this extension of the methodology ‘Multi-Tox’ (Fig. 1b).
2. Materials and methods
2.1. Plasmids
pTox7 [13] (gifted fromD. Langosch, TechnischeUniversitätMünchen,
Germany) was modiﬁed by insertion mutagenesis to add one base (t)
directly following the BamHI restriction site. pTox7 TM5 and pTox7 TM1
were created by ligating double stranded synthetic oligonucleotides into
the NheI/BamHI sites of modiﬁed pTox7. Double stranded oligonucleo-
tides encoding TM5 and TM1 were obtained from Integrated DNA
Technologies (IA, USA). pTox7 TM5 D150A was created using standard
site directed mutagenesis with a commercially available Stratagene
Quikchange II kit (Agilent, CA, USA). pTox7 TMD456 was prepared by
ligating two sequential double stranded synthetic oligonucleotides
(Integrated DNA Technologies, IA, USA) into the NheI/BamHI sites of
modiﬁed pTox7 in one pot. TMD inserts for TMD123, TMD234, TMD345
andDAGKwere prepared commercially byGenewiz (NJ, USA),ﬂanked by
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Fig. 1. Cartoon representations of (a) ToxR and (b)Multi-Tox assays. Maltose-binding protein (MBP) locates to the periplasm, forcing a parallel orientation of TMDs in themembrane.
TMD-driven oligomerization results in dimerization of ToxR and activation of signaling by the ctx promoter.
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pUC57, exerts were ligated into modiﬁed pTox7. All transmembrane
sequences were codon-optimized for E. coli. TMD mutants were created
using standard site directed mutagenesis with a commercially available
Stratagene Quikchange II kit (Agilent, CA, USA).
2.2. ToxR assay
ToxR plasmids (200 ng) were transformed into 200 μl FHK12
competent cells (kindly provided by D. Langosch, Technische
Universität München, Germany) with heat shock at 42 °C for 90 s
and incubation on ice for 2 min, followed by addition of 800 μl SOC
medium and incubationwith shaking at 37 °C for 1 h. An aliquot of the
transformation mixture (50 μl) was used to inoculate 5 ml LB broth in
the presence of arabinose (0.0025%) and chloramphenicol (30 μg/ml)
in triplicate. Cultures were incubated with shaking at 37 °C for 20 h
and β-galactosidase activity was measured using a Beckman Coulter
DTX 880 plate reader (Beckman Coulter, CA, USA) as follows: 5 μl of
each culture was transferred in quadruplicate to the wells of a Costar
3596 polystyrene 96-well plate (Corning, NY, USA) containing 100 μl
Z buffer/chloroform (1% β-mercaptoethanol, 10% chloroform, 89% A
buffer: 1 M sodium phosphate, 10 mM KCl, 1 mMMgSO4 pH 7.0). Cell
densities were recorded by measuring OD595. Cells were lysed by
addition of 50 μl Z sodium dodecyl sulfate (SDS) in Z buffer (1.6% w/v)
and shaking at 28 °C for 10 min. To the resultant mixture, 50 μl ortho-
nitrophenyl β-galactoside (ONPG) in Z buffer (0.4% w/v) was added
and β-galactosidase activity wasmeasured bymonitoring the reaction
at 405 nm for a period of 20 min at intervals of 30 s at 28 °C. Miller
Units were calculated using the following equation:
Miller Units =
OD405 =min
OD600
× 1000
2.3. DN-ToxR assay
Both pTox6 [14] and plasmid control [13] were kindly provided by
D. Langosch, Technische Universität München, Germany and pTox6
was modiﬁed by insertion of a single base (t) after the BamHI
restriction site using standard Quikchangemutagenesis protocols. The
pTox6 variant containing LMP-1 TMD456 was prepared as described
for pTox7 above. DN-assays were carried out in an analogous manner
to ToxR assays except double volumes of FHK12 competent cells and
SOCwere used for dual transformations and selectionwas achieved by
addition of chloramphenicol (30 μg/ml) and kanamycin (33 μg/ml).
2.4. Control experiments
Western blotting was performed with antiserum recognizing the
maltose binding protein moiety of the constructs (New England
Biolabs, MA, USA). The chemiluminescence outputwas captured usingeither X-ray ﬁlm or a CCD camera imaging device and the 60–70 kDa
region of the blot is shown. The color of images captured using X-ray
ﬁlmwas inverted. Controls formembrane integrationwere performed
by transforming PD28 cells with the indicated plasmids. Cells were
grown in minimal media with 0.4% maltose as the sole carbon source.
Cell density wasmonitored by OD595 and corresponds to the efﬁciency
of membrane integration. PD28 cells were kindly provided by D.
Langosch, Technische Universität München, Germany.
3. Results and discussion
3.1. Multi-Tox analysis of membrane-integral diacylglycerol kinase
oligomerization
In order to study multi-pass TMD oligomerization, chimeric
proteins comprised of maltose binding protein (MBP) for location to
the periplasm, the polytopic TMD of interest and the DNA-binding
domain of ToxR for signaling were expressed in the E. coli indicator
strain, FHK12. TMD-driven oligomerization facilitates dimerization of
ToxR, leading to transcriptional activation of the ctx promoter and
expression of β-galactosidase. The level of β-galactosidase correlates
to the oligomerization propensity of the TMD (Fig. 1b).
Awell-studied triple-passprotein,membrane-integraldiacylglycerol
kinase (DAGK) from E. coli, was chosen as amodel system to validate the
Multi-Tox assay. Previous biochemical and structural analyses have
assessed various DAGK TMD residues for their ability to disrupt
oligomerization [15]. A vector for expression of a chimeric protein
containing the entire DAGK TMD (MBP–DAGK TMD–ToxR) was
constructed and standard site-directed mutagenesis was performed to
introduce six individual point mutations in the transmembrane region
(Fig. 2c). Expression of the chimeric proteins in E. coli and quantiﬁcation
of β-galactosidase levels was performed. Multi-Tox analysis of oligo-
merization of the entire DAGK TMD (three-pass) agreed with earlier
ﬁndings reported by Sanders and co-workers [15]; the A100C mutation
has been identiﬁed to destabilize trimerization and this was indeed
observed in our assay,whilstmutations reported to havemodest or little
effect on trimerization (E69C and N72C) showed no signiﬁcant
reduction of oligomerization (Fig. 2a). Interestingly, K94C, a mutation
for which the effect on trimerization was previously described as
‘unclear,’ did affect oligomerization propensity in our assay, suggesting
potential oligomerization/structure stabilization roles played by this
lysine residue at the membrane/aqueous interface. A double mutant of
K94C andA100C showed a small additive effect on the association of the
DAGK TMD, reconﬁrming the previously identiﬁed importance of A100
in the third transmembranehelix andhighlighting a role for neighboring
K94. To further understand the effects of simultaneously mutating
residues on different DAGK TM helices, a triple mutant (E69C, K94C,
A100C) was constructed. The E69C mutation exerted only a small
negative change in oligomerization propensity, both as a single mutant
or as part of the triple mutant. These results agree well with the
previously reportedX-ray crystal structure ofDAGK [15]where theE69C
cb
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Fig. 2. (a) Analysis of key residues in the DAGK TMD by Multi-Tox. Error bars represent the standard deviation of three replicates, each measured in quadruplicate. Inset:
classiﬁcation of DAGK mutants for disruption of trimerization as previously reported [15]; (b) Western blots of protein expression for DAGK TMD; (c) Cartoon representation of the
MBP-DAGK-ToxR Multi-Tox chimeric protein, summarizing the DAGK residues investigated. DAGK residues are numbered according to the wild-type unmodiﬁed DAGK protein.
Arrows indicate direction of numbering for each helix turn.
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propensity, suggesting that fusionwith the ToxR andMBP segments did
not signiﬁcantly alter the conformation of the DAKG TMD. Therefore,
Multi-Tox may provide a useful tool for mapping TM helix-helix
interfaces by examination of the cumulative effects of multiple
mutations on different helices. Expression of the chimeric protein was
conﬁrmedbyWesternblottingagainstmaltose bindingprotein (Fig. 2b),
showing that all analogs were expressed at a comparable level.
3.2. Multi-Tox analysis of latent membrane protein-1 oligomerization
The clinically relevant oncoprotein, latent membrane protein-1
(LMP-1) [16] was chosen as a secondary validation of the Multi-Toxmethodology to ensure that the assay would be effective with non-
bacterial transmembranedomain inserts. LMP-1 is a viral transforming
protein essential for B cell immortalization by Epstein-Barr Virus (EBV)
[16], playing a key role in EBV-dependent malignancies [17,18]. The
six-pass transmembrane domain of LMP-1 plays a critical role in the
aberrant signaling of this protein [19]; intermolecular hydrogen
bonding of a buried aspartic acid residue (D150) in TM5 drives
oligomerization to form a constitutively activated complex [20,21].
Although self-association of LMP-1 via its TMD is documented [19], the
native oligomeric state of the protein has yet to be determined.
However, key features of the oligomerization mechanism have
recently been elucidated. Our group has previously shown that TM5
elicits a strong response in the ToxR assay, comparable to the classic
Fig. 3. Comparison of the oligomerization of LMP-1 (a) single-pass transmembrane domains (TMs) by ToxR assay and (b) triple-pass LMP-1 constructs by Multi-Tox assay. Western
blots of chimeric protein expression for (c) LMP-1 single-pass transmembrane domains, (d) LMP-1 triple-pass transmembrane domains and (e) LMP-1 single-pass transmembrane
domains compared to LMP-1 triple-pass transmembrane domains. (f) Maltose complementation assay demonstrating correct location of MBP to the periplasm. Control represents
plasmid control, lacking the MBP reading frame. Error bars represent the standard deviation of three replicates, each measured in quadruplicate.
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benchmark for transmembrane domain association (Fig. 3a) [3,4].
Mutation of the critical TM5membrane-embedded aspartic acid to an
alanine (D150A) results in signiﬁcant attenuation of signal. By con-
trast, TM1, a different transmembrane helix of LMP-1, exhibits little
propensity to oligomerize, with a signal just above that for untrans-
formed cells (blank).
Multi-Toxwas employed to further study oligomerization of LMP-1
transmembrane helices together with their nearest sequential
neighbors; every three-transmembrane domain combination, i.e.
TMD123, TMD234, TMD345 and TMD456, was cloned into the ToxR
reporter system as MBP-TMD-ToxR chimeric proteins. The TMD DNA
sequence was codon optimized for E. coli to facilitate optimal protein
expression. In addition, D150A mutants were produced for any
sequence containing helix ﬁve. Initial Multi-Tox results were in strong
agreement with previous ToxR data. The two constructs containing
helix ﬁve (TMD345 and TMD456) exhibited increased interaction
propensities in comparison to TMD123 and TMD234, which did not
contain helix 5 (Fig. 3b). TMD345 exhibited a particularly strong
signal, approximately double the signal for TMD456, perhaps due to
the TMD345-ToxR construct presenting ToxR in a more favorable
conformation and/or orientation for oligomerization.
In Multi-Tox, a marked reduction in signal was observed when
LMP-1 wild-type sequences were compared to D150A mutants. The
predictable behavior of these chimeric proteins in comparison to their
mutants indicates that multi-pass constructs are capable of signaling
in a sequence-dependent manner. It is possible to get useful
information by studying truncated LMP-1 in this manner because
transmembrane helices have a high level of intrinsic stability due tothe energetic requirement to sequester the polar backbone from the
hydrophobic environment of the membrane, causing them to adopt
native-like structures. As an elegant example, Engelman and co-
workers demonstrated that analyses of individual transmembrane
helices of bacteriorhodophsin could shed light on membrane protein
folding and interactions [22]. Additionally, a number of previous
studies into the cellular function of LMP-1 have employed chimeric
proteins incorporating different truncations of the LMP-1 TMD (e.g.
TMD12, TMD 123, etc.) in order to study the dependence on cell
signaling, e.g. via NFκB. Such studies demonstrate the ability of a
partial multi-pass LMP-1 TMD to fold correctly and retain functional
ability [23,24].
Protein expression was conﬁrmed by Western blotting against
C-terminalMBP for ToxR constructs (Fig. 3c) andMulti-Tox constructs
(Fig. 3d). It must be noted that the overall β-galactosidase signal level
was markedly lower for Multi-Tox and protein expression of the
multi-pass construct was shown to be correspondingly lower (Fig. 3e)
in comparison to the single-pass Tox systems. Reduced expression
levels are hardly surprising, given the well-documented difﬁculties
associated with expressing eukaryotic membrane proteins in E. coli;
(expression levels for the DAGK series were signiﬁcantly higher than
for LMP-1 constructs). However, it appears that high expression levels
are not required for robust determination of oligomerization propen-
sity; despite the decreased protein expression level, sequences contain-
ing oligomerization-prone TM5 exhibit signiﬁcantly higher signals and
the assay is fully able to distinguish between oligomerization
propensities of TMD456 and TMD456 with the known disrupting
mutation D150A. An important notion is that although ToxR assays can
be used to compare relative oligomerization propensities of unrelated
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Fig. 4. Dominant-negative (DN) ToxR andMulti-Tox assays of LMP-1 constructs for analysis of heterotypic interactions. (a) Interaction of ToxR-TM5with signaling-deﬁcient ToxR*-TM5;
(b) Interaction of ToxR-TMD456with signaling deﬁcient ToxR*-TMD456;Westernblots for (c) theDN-ToxR assay and (d) theDN-Multi-Tox assay. Control plasmiddoesnot contain either
the ToxR or the MBP reading frame. Error bars represent the standard deviation of three replicates, each measured in quadruplicate.
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modiﬁcation of helix length has been shown to affect readout in some
cases [3]. Nevertheless, data gained from ToxR studies, especially in
combination with other evidence, provides useful insight into the
likelihood of a sequence having a high or low propensity to oligomerize.
Comparisons can bemade withmuch greater conﬁdence, when a wild-
type sequence is comparedwith a mutant sequence of the same length.
Finally, proper location of the chimeric constructs to the periplasm
was conﬁrmed by maltose complementation assay (Fig. 3f). PD28
cells, which lack naturally occurring periplasmic MBP, were grown on
minimal media with maltose as the sole carbon source. Only cells
expressing successfully folded protein with MBP located to the
periplasm can internalize maltose and grow. These results lend
support that Multi-Tox tests the association of transmembrane helices
without perturbing their folding or insertion, presenting a native-like
system to study multi-pass membrane protein–protein interactions.
3.3. Dominant-negative Multi-Tox analysis of latent membrane protein-1
Heteromeric interactions between single-pass transmembrane
helices have been studied by dominant-negative ToxR (DN-ToxR)
assay [13]. In this assay cells are transformed with two plasmids, one
expressing the wild-type ToxR construct and one expressing a ToxR
variant inactivated by a single point mutation (ToxR*). Strong TMD
hetero-oligomerization results in all signaling competent ToxR pro-
teins being sequestered into signaling-incapable heterodimers. The
behavior of multi-pass constructs mirrored that of single-pass
counterparts; signaling was completely knocked-down indicating
strong association for TMD456 with itself (Fig. 4b and a respectively).
Simultaneous expression of the pair of chimeric proteins was
conﬁrmed by Western blotting (Fig. 4c and d). These data showed
that Multi-Tox can be carried out in the dominant-negative format,
expanding its scope to study a wide variety of hetero- as well as
homo-oligomeric protein–protein interactions.
4. Conclusions
Elucidating the roles of the transmembrane domains of a multi-pass
integral membrane protein is a complex undertaking. Where a
functional role involving interaction, either heteromeric or homomeric,
is suspected, the ToxR reporter family of assays can provide invaluable
information. Our results demonstrate that incorporation of a triple-
transmembrane pass into the ToxR system, giving a ‘Multi-Tox’ chimera
provides a useful tool for the study of such interactions in thehomomeric or dominant-negative format. Currently, the assay is limited
by protein expression levels to studies of triple-TM chimeras, however
investigations to expand the scope of Multi-Tox are currently ongoing.
Nevertheless, the application of triple-transmembrane domains to the
ToxR reporter assay signiﬁcantly increases its potential applications and,
in this study, we applyMulti-Tox, to provide further evidence of the key
functional roles of the TMDs of two integral membrane proteins, DAGK
and LMP-1.
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